Company Overview of Asuragen, Inc.
Asuragen, Inc., a RNA-based therapeutic and diagnostics company, provides molecular biology services. The company focuses on molecular oncology and genetic diseases, with emphasis on microRNA (miRNA). It offers diagnostic products, such as Signature genetic testing and oncology testing products, as well as controls and standards. The company also offers nucleic acid-based services, including analyte isolation/preparation, genomic profiling, miRNA/mRNA expression profiling, biomarker discovery, assay design and validation, CLIA-based clinical testing, bioinformatics, and regulatory and project management. In addition, it offers gene expression profiling, genotyping, miRNA expression profiling...
2150 Woodward Street
Austin, TX 78744
Founded in 2005
Key Executives for Asuragen, Inc.
Chief Executive Officer and President
Senior Vice President and General Counsel
Senior Director of Clinical Affairs
Compensation as of Fiscal Year 2014.
Asuragen, Inc. Key Developments
Asuragen Receives New York State License for Molecular Genetic and Oncology Clinical Laboratory Testing
Jul 10 14
Asuragen, Inc. announced that it had received a clinical laboratory permit from the state of New York to offer Xpansion Interpreter, its reflex test for fragile X carriers and miRInform Thyroid for use in the management of patients with thyroid nodules. With this approval, Asuragen can now offer its CAP-certified CLIA laboratory Xpansion Interpreter and miRInform Thyroid Tests in all 50 states. Fragile X syndrome is the most common inherited cause of intellectual disability and autism. The likelihood of having a child with fragile X syndrome is linked to the number of CGG repeats and the number of AGG interruptions in the Fragile X Mental Retardation (FMR1) gene. Xpansion Interpreter is the first clinically available laboratory-developed FMR1 test that determines the total number of CGG repeats and number of AGG interruptions. Xpansion Interpreter can aid in personalizing the risk for at-risk patients of having a child with fragile X syndrome. Features of fragile X syndrome vary widely but can include mild to severe cognitive delays, seizures, behavioral differences such as perseverative speech and hand flapping, and characteristic facial features such as large ears and a long face. About 1 in 4,000 males and 1 in 8,000 females has fragile X syndrome. The molecular basis for fragile X syndrome is an increased number of trinucleotide CGG repeats in the 5' promoter region of the FMR1 gene. FMR1 alleles can be further categorized based on the number of CGG repeats, and premutation alleles may expand from parent to child to a full mutation that can cause features of fragile X syndrome. In addition, people with premutations may develop fragile X-associated Tremor/Ataxia Syndrome and women may develop fragile X-associated Primary Ovarian Insufficiency.
Asuragen Receives Notice of Patent Allowance for Broad Diagnostic Application of miR-21 in Cancer
Oct 8 13
Asuragen, Inc. announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 12/890,398 with claims covering the detection of miR-21 across all cancers and for all sample types. miR-21 is over-expressed in almost all solid tumors including breast, colon, esophageal, head and neck, lung, pancreas, prostate, and stomach cancers. It is the only miRNA that is up regulated in nearly all classes of human cancers derived from connective tissues and epithelial, hematopoietic, germ or nervous cells. Further supporting the ubiquitous oncogenic role of miR-21, multiple scientific publications have shown that miR-21 plays an important role in virtually every cellular process involved in tumor development such as proliferation, angiogenesis, replicative immortalization, invasion and metastasis, genome instability and mutation, tumor-promoting inflammation, deregulation of cellular metabolism, evading growth suppressors, immune destruction and cell death.
Asuragen, Inc. Presents at 12th Annual BIO Investor Forum, Oct-09-2013 03:00 PM
Aug 9 13
Asuragen, Inc. Presents at 12th Annual BIO Investor Forum, Oct-09-2013 03:00 PM. Venue: The Palace Hotel, 2 New Montgomery Street, San Francisco, CA 94105, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|